Business Insider

International Atherosclerosis Society & Residual Risk Reduction Initiative Publish Consensus Statement on New Treatment for Residual Cardiovascular Risk

MILAN and BASEL, Switzerland, Sept. 2, 2019 /PRNewswire/ -- A new highly selective treatment, a peroxisome proliferator-activated receptor alpha modulator (SPPARM-alpha) agonist, may help to address ...
Healio

Residual CVD risk varies; individualized treatments best to combat it

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Healio

FDA approves CV version of colchicine for patients with residual inflammatory risk

Please provide your email address to receive an email when new articles are posted on . A 0.5 mg dose of colchicine has been approved for use in high-risk patients who have inflammatory risk. The dose ...